ClinicalTrials.gg
CompletedNCT04567329Updated Aug 19, 2024Results posted

Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

A Phase 3 interventional study of NOV03 and Saline Solution in Dry Eye Disease, sponsored by Bausch & Lomb Incorporated. Completed at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
620
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing perfluorohexyloctane in Dry Eye Syndromes — 1 open to participants now, 2 under way, none of them phase 3. perfluorohexyloctane · Dry Eye Syndromes.

Enrollment
Largest of 13
620 · median 216
Started
2020
with 2 others
Phase 3
4 of 13
none open now
Registered
4th of 13
by date
Lead sponsor
9 of 13
Bausch & Lomb Incorporated

Among the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, this one has the largest enrollment, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 4th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About perfluorohexyloctane

perfluorohexyloctane: first FDA approval 2023 (MIEBO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).

03

Conditions studied

  • Dry Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Was at least 18 years of age at the time of consent.
  2. Provided written .
  3. Had a subject-reported history of DED in both eyes for at least 6 months prior to Visit 0.
  4. Had a TFBUT ≤5 seconds at Visit 0 and Visit 1.
  5. Had an OSDI score ≥25 at Visit 0 and Visit 1.
  6. Had an unanesthetized Schirmer's test I score ≥5 mm at Visit 0 and Visit 1.
  7. Had MGD defined as total MGD score ≥3 at Visit 0 and Visit 1 (secretion of 5 central glands on the lower eyelid was evaluated, and each was scored from 0-3: 0 = normal; 1 = thick/yellow, whitish, particulate; 2 = paste; 3 = none/occluded). Total score ranged from 0-15.
  8. Had a tCFS score between 4 and 11 (ie, sum of inferior, superior, central, nasal, and temporal) according to the NEI scale at Visit 0 and Visit 1.
  9. Had at least one eye (the same eye) that satisfied all criteria for 4, 6, 7, and 8 above at Visit 0 and Visit 1.
  10. Was able and willing to follow instructions, including participation in all trial assessments and visits.

Exclusion criteria

Exclusion Criteria:

A subject was excluded from participating in the study if he or she met any of the following criteria:

  1. Had been randomized in NVU-002 or NVU-003 study or had participated in the NVU-004 open-label extension (OLE) study.
  2. Had any ocular surface slit-lamp findings at Visit 0 and Visit 1 and/or in the opinion of the Investigator had any findings that may have interfered with trial parameters, including eye trauma or history of eye trauma or anterior membrane dystrophy.
  3. Had a history of Stevens-Johnson syndrome.
  4. Had active blepharitis or lid margin inflammation that required any topical antibiotics or topical within last 30 days prior to Visit 0 or would have likely required such treatment during the trial. Any other lid margin therapy such as lid scrubs, lid wipes, warm compresses, systemic antibiotics (such as tetracyclines) and oral supplements for treatment of ocular conditions had to be stable within the last 30 days prior to Visit 1 and was to be maintained throughout the trial.
  5. Had had a LipiFlow procedure, intense pulse light procedure or any kind of other procedure affecting meibomian glands within 6 months prior to Visit 1.
  6. Had abnormal lid anatomy that caused incomplete eyelid closure, including entropion and ectropion, or floppy lid syndrome that exposed parts of the conjunctiva or impaired the blinking function of the eye.
  7. Had received or removed a permanent punctum plug within 3 months (6 months for dissolvable punctum plugs) prior to Visit 1 or was expected to receive a punctum plug or removal of a punctum plug, or had a punctum plug expected to be dissolved during the trial.
  8. Had DED secondary to scarring, irradiation, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells (as with vitamin A deficiency).
  9. Had an ocular or periocular .
  10. Had a corneal epithelial defect or had significant confluent staining or filaments anywhere on the cornea.
  11. Had a history of herpetic keratitis.
  12. Had active ocular allergies or ocular allergies that were expected to be active during the trial period.
  13. Was diagnosed with an active ocular or systemic infection (bacterial, viral, or fungal), including fever requiring treatment with antibiotics.
  14. Had worn contact lenses within 1 month of Visit 0 or anticipated using contact lenses during the trial.
  15. Had used any eye drops and/or TrueTearTM device (intranasal tear neurostimulator) within 24 hours before Visit 1.
  16. Had undergone intraocular surgery or ocular laser surgery within the previous 6 months or had any planned ocular and/or lid surgeries over the trial period.
  17. Was a family member living in the same household as another subject who was randomized into Study 904 or NVU-003 or participated in NVU-004 OLE.
  18. Was a clinical site employee directly involved in the management, administration, or support of this trial or was an immediate family member of the same.
  19. Was a woman who was pregnant, nursing or planning a pregnancy.
  20. Was unwilling to submit to a urine pregnancy test at Visit 0, Visit 1 and Visit 4 (or early termination visit) if of . Non-childbearing potential was defined as a woman who was permanently sterilized (eg, had a hysterectomy or bilateral tubal ligation or bilateral oophorectomy) or was (without menses for 12 consecutive months).
  21. Was a woman of childbearing potential who was not using an acceptable means of ; acceptable methods of contraception included: hormonal (oral, implantable, injectable, or transdermal contraceptives); mechanical (spermicide in conjunction with a barrier such as a diaphragm or condom); intrauterine device; or surgical sterilization of partner. For non-sexually active females, abstinence could have been regarded as an adequate method of birth control; however, if the subject became sexually active during the trial, she had to agree to use adequate birth control as defined above for the remainder of the trial.
  22. Had an uncontrolled systemic disease in the opinion of the Investigator.
  23. Had a known allergy and/or sensitivity to the drug or saline components.
  24. Had active ocular or periocular rosacea that in the judgement of the Investigator interfered with the trial (eg, clinically relevant lid induration).
  25. Had a pterygium in any eye.
  26. Was currently enrolled in an investigational drug or device study or had used an investigational drug or device within 60 days of Visit 1.
  27. Had used any topical ocular steroids treatments, topical cyclosporine, lifitegrast, serum tears or topical anti-glaucoma medication within 60 days prior to Visit 0.
  28. Had used any oral medications known to cause ocular drying (eg, antihistamines, antidepressants, etc.) on a non-stable regimen within 1 month prior to Visit 0 or was expected to be unstable during the trial.
  29. Had corrected VA worse than or equal to logarithm of the minimum angle of resolution (LogMAR), +0.7 as assessed with Early Treatment Diabetic Retinopathy Study (ETDRS) charts in both eyes at Visit 0 and Visit 1.
  30. Had a condition or was in a situation (including language barrier) that the Investigator felt put the subject at significant risk, may have confounded the trial results, or may have interfered significantly with the subject's participation in the trial.
  31. Had a history of isotretinoin (eg, Accutane, Myorisan, Claravis, Amnesteem) use.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
620 participants (actual)

Study arms

  • Experimental
    NOV03

    100% perfluorohexyloctane 4 times daily (QID)

    Drug: NOV03

  • Placebo comparator
    Saline solution

    0.6% sodium chloride solution 4 times daily (QID)

    Drug: Saline Solution

Interventions

  • DrugNOV03

    100% perfluorohexyloctane

  • DrugSaline Solution

    0.6% sodium chloride solution

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Corneal Fluorescein Staining Score (NEI Scale) in the Study Eye at Day 57

    The National Eye Institute (NEI) scale relies on a chart that divides the cornea into five sections (central, superior, temporal, nasal, and inferior) and assigns a value from 0 (absent) to 3 (severe) to each section, based on the amount, size, and confluence of the punctate keratitis, for a maximum total score of 15 points (sum of scores for each section).

    Time frame: Assessed at Day 57

  2. Change From Baseline in Dryness Score (Visual Analogue Scale [VAS] Severity of Dryness) at Day 57

    Study staff will ask participants to rate their severity of ocular dryness (both eyes simultaneously) by placing a vertical mark on a horizontal line to indicate the level of discomfort (0 corresponds to "no dryness" and 100% corresponds to "maximal dryness").

    Time frame: Assessed at Day 57

Secondary outcomes

  1. Change From Baseline in Dryness Score (Visual Analogue Scale [VAS] Severity of Dryness) at Day 15

    Study staff will ask participants to rate their severity of ocular dryness (both eyes simultaneously) by placing a vertical mark on a horizontal line to indicate the level of discomfort (0 corresponds to "no dryness" and 100% corresponds to "maximal dryness").

    Time frame: Assessed at Day 15

  2. Change From Baseline in Total Corneal Fluorescein Staining (NEI Scale) at Day 15

    The National Eye Institute (NEI) scale relies on a chart that divides the cornea into five sections (central, superior, temporal, nasal, and inferior) and assigns a value from 0 (absent) to 3 (severe) to each section, based on the amount, size, and confluence of the punctate keratitis, for a maximum total of 15 points (sum of scores for each section).

    Time frame: Assessed at Day 15

  3. Change From Baseline in Burning/Stinging (Visual Analogue Scale [VAS] Severity of Burning/Stinging) at Day 57

    Subjects will be asked about the severity of burning / stinging. Study staff will ask subjects to rate their ocular symptoms (both eyes simultaneously) due to ocular dryness by placing a vertical mark on a horizontal line to indicate the level of discomfort (0 corresponds to "no discomfort" and 100% corresponds to "maximal discomfort").

    Time frame: Assessed at Day 57

  4. Change From Baseline in Central Corneal Fluorescein Staining (NEI Scale) at Day 57

    The National Eye Institute (NEI) scale relies on a chart that divides the cornea into five sections (central, superior, temporal, nasal, and inferior) and assigns a value from 0 (absent) to 3 (severe) to each section, based on the amount, size, and confluence of the punctate keratitis, for a maximum of 3 points in the central section.

    Time frame: Assessed at Day 57

07

Results

Posted Aug 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneNOV03Saline Solution
Started311309
Completed302296
Not completed913
Withdrew: Withdrawal by subject56
Withdrew: Protocol violation23
Withdrew: Discontinued22
Withdrew: Lost to follow-up01
Withdrew: Lack of efficacy01

Outcome measures

PrimaryChange From Baseline in Total Corneal Fluorescein Staining Score (NEI Scale) in the Study Eye at Day 57

The National Eye Institute (NEI) scale relies on a chart that divides the cornea into five sections (central, superior, temporal, nasal, and inferior) and assigns a value from 0 (absent) to 3 (severe) to each section, based on the amount, size, and confluence of the punctate keratitis, for a maximum total score of 15 points (sum of scores for each section).

Time frame:
Assessed at Day 57
Reported as:
Mean · units on a scale
Change From Baseline in Total Corneal Fluorescein Staining Score (NEI Scale) in the Study Eye at Day 57
units on a scaleNOV03Saline Solution
Change From Baseline in Total Corneal Fluorescein Staining Score (NEI Scale) in the Study Eye at Day 57-2.3 ± 2.8-1.1 ± 2.9
PrimaryChange From Baseline in Dryness Score (Visual Analogue Scale [VAS] Severity of Dryness) at Day 57

Study staff will ask participants to rate their severity of ocular dryness (both eyes simultaneously) by placing a vertical mark on a horizontal line to indicate the level of discomfort (0 corresponds to "no dryness" and 100% corresponds to "maximal dryness").

Time frame:
Assessed at Day 57
Reported as:
Mean · units on a scale
Change From Baseline in Dryness Score (Visual Analogue Scale [VAS] Severity of Dryness) at Day 57
units on a scaleNOV03Saline Solution
Change From Baseline in Dryness Score (Visual Analogue Scale [VAS] Severity of Dryness) at Day 57-29.5 ± 28.6-19.0 ± 27.2
SecondaryChange From Baseline in Dryness Score (Visual Analogue Scale [VAS] Severity of Dryness) at Day 15

Study staff will ask participants to rate their severity of ocular dryness (both eyes simultaneously) by placing a vertical mark on a horizontal line to indicate the level of discomfort (0 corresponds to "no dryness" and 100% corresponds to "maximal dryness").

Time frame:
Assessed at Day 15
Reported as:
Mean · units on a scale
Change From Baseline in Dryness Score (Visual Analogue Scale [VAS] Severity of Dryness) at Day 15
units on a scaleNOV03Saline Solution
Change From Baseline in Dryness Score (Visual Analogue Scale [VAS] Severity of Dryness) at Day 15-18.5 ± 23.6-10.5 ± 23.9
SecondaryChange From Baseline in Total Corneal Fluorescein Staining (NEI Scale) at Day 15

The National Eye Institute (NEI) scale relies on a chart that divides the cornea into five sections (central, superior, temporal, nasal, and inferior) and assigns a value from 0 (absent) to 3 (severe) to each section, based on the amount, size, and confluence of the punctate keratitis, for a maximum total of 15 points (sum of scores for each section).

Time frame:
Assessed at Day 15
Reported as:
Mean · units on a scale
Change From Baseline in Total Corneal Fluorescein Staining (NEI Scale) at Day 15
units on a scaleNOV03Saline Solution
Change From Baseline in Total Corneal Fluorescein Staining (NEI Scale) at Day 15-1.9 ± 2.3-1.3 ± 2.4
SecondaryChange From Baseline in Burning/Stinging (Visual Analogue Scale [VAS] Severity of Burning/Stinging) at Day 57

Subjects will be asked about the severity of burning / stinging. Study staff will ask subjects to rate their ocular symptoms (both eyes simultaneously) due to ocular dryness by placing a vertical mark on a horizontal line to indicate the level of discomfort (0 corresponds to "no discomfort" and 100% corresponds to "maximal discomfort").

Time frame:
Assessed at Day 57
Reported as:
Mean · units on a scale
Change From Baseline in Burning/Stinging (Visual Analogue Scale [VAS] Severity of Burning/Stinging) at Day 57
units on a scaleNOV03Saline Solution
Change From Baseline in Burning/Stinging (Visual Analogue Scale [VAS] Severity of Burning/Stinging) at Day 57-22.1 ± 27.5-13.7 ± 29.9
SecondaryChange From Baseline in Central Corneal Fluorescein Staining (NEI Scale) at Day 57

The National Eye Institute (NEI) scale relies on a chart that divides the cornea into five sections (central, superior, temporal, nasal, and inferior) and assigns a value from 0 (absent) to 3 (severe) to each section, based on the amount, size, and confluence of the punctate keratitis, for a maximum of 3 points in the central section.

Time frame:
Assessed at Day 57
Reported as:
Mean · units on a scale
Change From Baseline in Central Corneal Fluorescein Staining (NEI Scale) at Day 57
units on a scaleNOV03Saline Solution
Change From Baseline in Central Corneal Fluorescein Staining (NEI Scale) at Day 57-0.4 ± 0.8-0.1 ± 0.9

Adverse events

Collected over Assessed through the study, approximately 8 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NOV030/311 (0%)0/311 (0%)16/311 (5.1%)
Saline Solution0/309 (0%)0/309 (0%)19/309 (6.1%)
Most frequent other events
Most frequent other events
EventNOV03Saline Solution
Eye disorderEye disorders16/31116/309
HyperaemiaVascular disorders0/3113/309

Baseline characteristics

Age, Continuous
Age, Continuous(years)NOV03Saline SolutionTotal
Mean53.3 ± 17.3853.8 ± 16.2653.6 ± 16.82
Sex: Female, Male
Sex: Female, Male(Participants)NOV03Saline SolutionTotal
Female250238488
Male6171132
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NOV03Saline SolutionTotal
Hispanic or Latino6365128
Not Hispanic or Latino248244492
Unknown or Not Reported000
08

Study locations

35 sites
  • Bausch Site 206
    Phoenix, Arizona 85032, United States
  • Bausch Site 202
    Garden Grove, California 92843, United States
  • Bausch Site 221
    Hemet, California 92545, United States
  • Bausch Site 214
    Inglewood, California 90301, United States
  • Bausch Site 226
    Murrieta, California 92562, United States
  • Bausch Site 213
    Santa Ana, California 92705, United States
  • Bausch site 236
    Westminster, California 92683, United States
  • Bausch site 225
    Grand Junction, Colorado 81501, United States
  • Bausch Site 211
    Delray Beach, Florida 33484, United States
  • Bausch Site 204
    Morrow, Georgia 30260, United States
  • Bausch Site 209
    Chicago, Illinois 60616, United States
  • Bausch site 218
    Hoffman Estates, Illinois 60169, United States
  • Bausch Site 230
    Overland Park, Kansas 66210, United States
  • Bausch Site 207
    Louisville, Kentucky 40220, United States
  • Bausch Site 228
    Havre De Grace, Maryland 21078, United States
  • Bausch Site 231
    Bloomington, Minnesota 55431, United States
  • Bausch Site 229
    Saint Louis, Missouri 63128, United States
  • Bausch Site 224
    Saint Louis, Missouri 63131, United States
  • Bausch Site 217
    Washington, Missouri 63090, United States
  • Bausch Site 208
    Rochester, New York 14618, United States
  • Bausch Site 210
    Asheville, North Carolina 28803, United States
  • Bausch site 233
    High Point, North Carolina 27262, United States
  • Bausch site 232
    Southern Pines, North Carolina 28387, United States
  • Bausch Site 201
    Cincinnati, Ohio 45247, United States
  • Bausch Site 216
    Cleveland, Ohio 44115, United States
  • Bausch Site 223
    Columbus, Ohio 43215, United States
  • Bausch Site 215
    Nashville, Tennessee 37215, United States
  • Bausch site 235
    Austin, Texas 78731, United States
  • Bausch Site 219
    Cedar Park, Texas 78613, United States
  • Bausch Site 212
    League City, Texas 77573, United States
  • Bausch site 234
    San Antonio, Texas 78209, United States
  • Bausch Site 222
    San Antonio, Texas 78215, United States
  • Bausch Site 203
    San Antonio, Texas 78230, United States
  • Bausch Site 220
    Norfolk, Virginia 23502, United States
  • Bausch Site 227
    Seattle, Washington 98119, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Aug 2021, 9 months.

Results were first posted in Aug 2024, 2 years 11 months after primary completion. A results delay was requested in May 2022.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 9 months is close to that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2020
First posted
Sep 28, 2020
StartActual
Nov 18, 2020
Primary completionActual
Aug 30, 2021
CompletionActual
Aug 30, 2021
Results delay requested
May 4, 2022
Results first posted
Aug 19, 2024
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04567329
Responsible party
Sponsor
First posted
Sep 28, 2020
Start date
Nov 18, 2020
Primary completion
Aug 30, 2021
Completion
Aug 30, 2021
Results posted
Aug 19, 2024
Last update
Aug 19, 2024

Study contacts

Daniel Donatello
study director · Bausch & Lomb Incorporated

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Perfluorohexyloctane

Start the discussion